Article
Biochemistry & Molecular Biology
Jeroen van Dorp, Christodoulos Pipinikas, Britt B. M. Suelmann, Niven Mehra, Nick van Dijk, Giovanni Marsico, Maurits L. van Montfoort, Sophie Hackinger, Linde M. Braaf, Tauanne Amarante, Charlaine van Steenis, Kirsten McLay, Antonios Daletzakis, Daan van den Broek, Maaike W. van de Kamp, Kees Hendricksen, Jeantine M. de Feijter, Thierry N. Boellaard, Richard P. Meijer, Toine G. van der Heijden, Nitzan Rosenfeld, Bas W. G. van Rhijn, Greg Jones, Michiel S. van der Heijden
Summary: Cohort 1 of the phase 1B NABUCCO trial showed high pCR rates with preoperative ipilimumab plus nivolumab in stage III UC. In cohort 2, dose adjustment was aimed to optimize responses. Absence of ctDNA in plasma can predict PFS in stage III UC patients treated with high-dose ipilimumab plus nivolumab.
Article
Health Care Sciences & Services
Fabiana Gregucci, Alessia Surgo, Roberta Carbonara, Letizia Laera, Maria Paola Ciliberti, Maria Annunziata Gentile, Morena Caliandro, Nicola Sasso, Ilaria Bonaparte, Vincenzo Fanelli, Romina Tortora, Eleonora Paulicelli, Giammarco Surico, Giuseppe Lombardi, Francesco Signorelli, Alba Fiorentino
Summary: The study evaluated the safety and efficacy of re-irradiation with radiosurgery or fractionated stereotactic radiotherapy in association with chemotherapy for recurrent high-grade gliomas. The results demonstrated that this treatment approach is safe and feasible for patients with recurrent HGG.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Oncology
Volker Moebus, Hans-Joachim Lueck, Ekkehart Ladda, Peter Klare, Marcus Schmidt, Andreas Schneeweiss, Eva-Maria Grischke, Grischa Wachsmann, Helmut Forstbauer, Michael Untch, Frederik Marme, Jens-Uwe Blohmer, Christian Jackisch, Jens Huober, Elmar Stickeler, Mattea Reinisch, Theresa Link, Bruno Sinn, Wolfgang Janni, Carsten Denkert, Jenny Furlanetto, Knut Engels, Christine Solbach, Sabine Schmatloch, Julia Rey, Nicole Burchardi, Sibylle Loibl
Summary: The interim analysis of the GAIN-2 trial showed no difference in invasive disease-free survival between intense dose dense (idd) and tailored dose-dense chemotherapy regimens, but tailoring treatment improved outcomes for patients with HR+/HER2-, lobular cancer, and those aged ≤50 years.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Panagiotis Tsagkozis, Czar L. Gaston, Emelie Styring, Felix Haglund, Robert Grimer
Summary: This study aimed to investigate the outcome of patients with high-grade osteosarcoma who had inadequate surgical margins. The results showed that good response to chemotherapy can salvage the outcome of surgical excision with poor margins, and a watchful waiting strategy may be justified in these cases.
JOURNAL OF SURGICAL ONCOLOGY
(2022)
Review
Multidisciplinary Sciences
Chengyu You, Xianhui Li, Yuelin Du, Hui Wang, Xiaojun Zhang, Tangqiang Wei, Anguo Wang
Summary: The combination of IAC with IVC is a safe and effective treatment for high-risk NMIBC, leading to significantly improved outcomes in terms of tumor recurrence, progression, tumor-specific death, PFS, and RFS, while the efficacy of IAC alone is comparable to IVC alone.
Article
Immunology
Yan Xiong, Ping Jiang, Shuhua Wei, Mengyuan Li, Yuhan Yang, Liting Xiong, Junjie Wang, Chunxiao Li
Summary: Natural killer cells play important roles in tumor immunosurveillance and are the first responders to recognize abnormal cells. The effect of high-dose radiotherapy on NK cells remains unclear. This study showed that high-dose radiotherapy shaped an immunosuppressive tumor microenvironment and inhibited the function of NK cells. However, the combination of radiotherapy and TIGIT inhibition significantly enhanced the effect of radiotherapy and decreased tumor recurrence.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Oncology
Yu-Ting Jiang, Kai-Hua Chen, Jie Yang, Zhong-Guo Liang, Ling Li, Song Qu, Xiao-Dong Zhu
Summary: This study revealed that for locoregionally advanced nasopharyngeal carcinoma, high-risk patients could benefit from a higher cumulative cisplatin dose in terms of 3-year progression-free survival and distant metastasis-free survival, while low-risk patients did not show significant survival advantages. A high cisplatin dose increased treatment-related acute toxicities.
Review
Oncology
Katherine Belanger, Timothy H. Ung, Denise Damek, Kevin O. Lillehei, D. Ryan Ormond
Summary: In this retrospective analysis, the efficacy of TMZ chemoradiation for the treatment of high-grade and recurrent meningiomas was compared to historical controls. The results showed no significant difference in PFS and OS between the two groups, suggesting that further research is needed to find novel treatment methods for malignant and recurrent meningiomas.
Review
Oncology
Lucie Lafay-Cousin, Christelle Dufour
Summary: Medulloblastoma is the most common malignant tumor in the pediatric population, and treatment strategies vary based on different factors. The best survival rates currently come from maximal surgical resection followed by craniospinal irradiation and chemotherapy. However, there are still challenges and limitations in the use of chemotherapy for metastatic disease, infants, and young children.
Article
Oncology
Shreya Armstrong, Yatman Tsang, Gerry Lowe, Hannah Tharmalingam, Roberto Alonzi, Peter Ostler, Robert Hughes, Peter Hoskin
Summary: The study found no association between biochemical recurrences and HDR BT dosimetry in patients receiving 19 Gy single fraction HDR BT. The majority of recurrences occurred at the original disease site.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Raphael Koch, Hans Gelderblom, Lianne Haveman, Benedicte Brichard, Heribert Juergens, Sona Cyprova, Henk van den Berg, Wolf Hassenpflug, Anna Raciborska, Torben Ek, Daniel Baumhoer, Gerardine Egerer, Hans Theodor Eich, Marleen Renard, Peter Hauser, Stefan Burdach, Judith Bovee, Fiona Bonar, Peter Reichardt, Jarmila Kruseova, Jendrik Hardes, Thomas Kuhne, Torsten Kessler, Stephane Collaud, Marie Bernkopf, Trude Butterfass-Bahloul, Catharina Dhooge, Sebastian Bauer, Janos Kiss, Michael Paulussen, Angela Hong, Andreas Ranft, Beate Timmermann, Jelena Rascon, Volker Vieth, Jukka Kanerva, Andreas Faldum, Markus Metzler, Wolfgang Hartmann, Lars Hjorth, Vivek Bhadri, Uta Dirksen
Summary: The study evaluated the effect of high-dose chemotherapy followed by reinfusion of autologous hematopoietic stem cells on survival in high-risk Ewing sarcoma patients. The results showed no benefit of TreoMel-HDT for the entire cohort, but it may be beneficial for patients younger than 14 years. This observation is supported by other studies.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Chunliang Cheng, Dongxu Qiu, Jinbo Chen, Xiongbing Zu, Jinhui Liu, Huihuang Li, Jiao Hu, Zhenglin Yi, Tongchen He, Zhi Chen, Yu Cui
Summary: The study confirmed the efficacy and toxicity of intra-arterial chemotherapy (IAC) plus intravesical chemotherapy (IVC) regimen for high-risk non-muscle-invasive bladder cancer (NMIBC). Compared to intravesical instillation, this treatment showed better therapeutic effect, with most adverse events being Grade I and II.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Shinichi Tate, Kyoko Nishikimi, Ayumu Matsuoka, Satoyo Otsuka, Kazuyoshi Kato, Yutaka Takahashi, Makio Shozu
Summary: The study investigated the efficacy and toxicity of tailored-dose chemotherapy with gemcitabine and irinotecan in patients with platinum-refractory/resistant ovarian or primary peritoneal cancer. Results showed that this tailored dosage chemotherapy was effective and well tolerated in these patients.
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
Benjamin M. Heyman, Michael Y. Choi, Thomas J. Kipps
Summary: Patients with Richter's Syndrome have a poor prognosis and traditional treatments are not effective. In this study, a novel chemotherapy-free combination of obinutuzumab, high-dose methylprednisolone, and lenalidomide was used to treat Richter's Syndrome patients, showing promising results.
Article
Surgery
Akhil Chawla, Motaz Qadan, Carlos Fernandez-del Castillo, Jennifer Y. Wo, Jill N. Allen, Jeffrey W. Clark, Janet E. Murphy, Onofrio A. Catalano, David P. Ryan, David T. Ting, Vikram Deshpande, Colin D. Weekes, Aparna Parikh, Keith D. Lillemoe, Theodore S. Hong, Cristina R. Ferrone
Summary: This study aimed to characterize the patterns of first recurrence after curative-intent resection for pancreatic adenocarcinoma (PDAC). The results showed that the pattern of recurrence in PDAC is predominantly distant metastasis (DM) rather than locoregional (LR), and this pattern remains consistent regardless of the use of neoadjuvant chemotherapy (NAC) and margin involvement.